In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
A new study investigating a single dose of psilocybin for the treatment of major depressive disorder (MDD) has shown clinically significant levels of reduction in depressive...
Japanese pharmaceutical company Otsuka Pharmaceutical has made one of Big Pharma’s first pivots into the psychedelics space with the acquisition of Mindset Pharma.
A new study has shown how trained human coders were able to identify observable markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy.
Launching in 2008 as a drug literature review blog by Rob Dickins, Psychedelic Press has brought readers a host of unique insights into psychedelic thought and...
Cybin Inc.
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
The Indigenous Medicine Conservation Fund (IMC Fund) took part in the 2023 Parliament of the World’s Religions (PoWR) held at McCormick Place Lakeside Center in Chicago,...
Psychedelics are known for inducing altered states of consciousness in humans by fundamentally changing our normal pattern of sensory perception, thought and emotion.
Enveric Biosciences has confirmed it has completed the manufacture of its lead drug candidate – EB-373 – a New Chemical Entity (NCE) designed as a next-generation...
Cybin Inc.
